Citations

Clear

6273 citation(s) found for "To, Andrew".

Antibody-mediated rejection despite inhibition of terminal complement
Bentall, Andrew , Tyan, Dolly B., Sequeira, Flavia, Everly, Matthew J. , Gandhi, Manish J. , Cornell, Lynn D. , Henderson, Nicole , Raghavaiah, Suresh , Dean, Patrick G. , Stegall, Mark D. , Li, Han , Winters, Jeffrey L. , Stegall, Mark D , Bentall, Andrew , Cornell, Lynn

Mayo Clinic

Transplant International | July 2, 2014 | Volume: 27 | Issue: 12 | Pages: 1235-1243

10.1111/tri.12396 | PMID 24990476 Get It

Thiazide Diuretic Prophylaxis for Kidney Stones and the Risk of Diabetes Mellitus
Singh, Prince , Knoedler, John, Krambeck, Amy E. , Bergstralh, Eric J., Knoedler, John J., Lieske, John C. , Rule, Andrew D.

Mayo Clinic

Journal of Urology | July 1, 2014 | Volume: 192 | Issue: 6 | Pages: 1700-1704

10.1016/j.juro.2014.06.078 | PMID 24992333 Get It

ACR Appropriateness Criteria ® Pre-Irradiation Evaluation and Management of Brain Metastases
Lo, Simon S. , Gore, Elizabeth , Bradley, Jeffrey D. , Buatti, John M. , Germano, Isabelle M. , Ghafoori, A. Paiman, Henderson, M. , Murad, Gregory J. A. , Patchell, Roy A., Patel, Samir H. , Robbins, Jared R. , Robins, H. Ian, Vassil, Andrew D. , Wippold, Franz J. , Yunes, Michael J. , Videtic, Gregory M.M. , Bradley, Jeffrey , Buatti, John M

Mayo Clinic

Journal of Palliative Medicine | June 27, 2014 | Volume: 17 | Issue: 8 | Pages: 880-886

10.1089/jpm.2014.9417 | PMID 24971478 Get It

Abstract Pretreatment evaluation is performed to determine the number, location, and size of the brain metastases and magnetic resonance imaging (MRI) is the recommended imaging technique, particularly in patients being considered for surgery or stereotactic radiosurgery. A contiguous thin-cut volumetric MRI with gadolinium with newer gadolinium-based agents can improve detection of small brain metastases. A systemic workup and medical evaluation are important, given that subsequent treatment for the brain metastases will also depend on the extent of the extracranial disease and on the age and performance status of the patient. Patients with hydrocephalus or impending brain herniation should be started on high doses of corticosteroids and evaluated for possible neurosurgical intervention. Patients with moderate symptoms should receive approximately 4–8 mg/d of dexamethasone in divided doses. The routine use of corticosteroids in patients without neurologic symptoms is not necessary. There is no proven benefit of anticonvulsants in patient without seizures. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed every 3 years by a multidisciplinary expert panel. The guideline development and review include an extensive analysis of current medical literature from peer reviewed journals and the application of a well-established consensus methodology (modified Delphi) to rate the appropriateness of imaging and treatment procedures by the panel. In those instances where evidence is lacking or not definitive, expert opinion may be used to recommend imaging or treatment.
A Review of the Application of Inflammatory Biomarkers in Epidemiologic Cancer Research
Brenner, Darren R. , Scherer, Dominique , Muir, Kenneth , Schildkraut, Joellen M. , Spitz, Margaret R., Goode, Ellen L. , Ulrich, Cornelia M. , Hung, Rayjean J., Hung, Rayjean J. , Boffetta, Paolo , Marchand, Loı̈c Le , Chan, Andrew T. , Hung, Rayjean J., Hung, Rayjean J , Muir, Kenneth

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | June 25, 2014 | Volume: 23 | Issue: 9 | Pages: 1729-1751

10.1158/1055-9965.epi-14-0064 | PMID 24962838 Get It

Abstract Inflammation is a facilitating process for multiple cancer types. It is believed to affect cancer development and progression through several etiologic pathways, including increased levels of DNA adduct formation, increased angiogenesis, and altered antiapoptotic signaling. This review highlights the application of inflammatory biomarkers in epidemiologic studies and discusses the various cellular mediators of inflammation characterizing the innate immune system response to infection and chronic insult from environmental factors. Included is a review of six classes of inflammation-related biomarkers: cytokines/chemokines, immune-related effectors, acute-phase proteins, reactive oxygen and nitrogen species, prostaglandins and cyclooxygenase-related factors, and mediators such as transcription factors and growth factors. For each of these biomarkers, we provide a brief overview of the etiologic role in the inflammation response and how they have been related to cancer etiology and progression within the literature. We provide a discussion of the common techniques available for quantification of each marker, including strengths, weaknesses, and potential pitfalls. Subsequently, we highlight a few under-studied measures to characterize the inflammatory response and their potential utility in epidemiologic studies of cancer. Finally, we suggest integrative methods for future studies to apply multifaceted approaches to examine the relationship between inflammatory markers and their roles in cancer development. Cancer Epidemiol Biomarkers Prev; 23(9); 1729–51. ©2014 AACR.
Use of JAK inhibitors in the management of myelofibrosis: a revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management o
Reilly, John T., Beer, Philip , Butt, Nauman M., Conneally, Eibhlin , Duncombe, Andrew , Green, Anthony R. , Mikhaeel, G., Gilleece, Maria , Knapper, Steven , Mead, Adam J. , Sekhar, Mallika , Harrison, Claire , McMullin, Mary Frances , Mesa, Ruben A. , Mead, Adam J , Knapper, Steven

Mayo Clinic

British Journal of Haematology | June 25, 2014 | Volume: 167 | Issue: 3 | Pages: 418-420

10.1111/bjh.12985 | PMID 24961987 Get It

All-Inside Anterior Cruciate Ligament Reconstruction
Blackman, Andrew J. , Stuart, Michael J.

Mayo Clinic

Journal of Knee Surgery | June 21, 2014 | Volume: 27 | Issue: 05 | Pages: 347-352

10.1055/s-0034-1381960 | PMID 24951949 Get It

Effectiveness of Anti-TNFα for Crohn Disease: Research in a Pediatric Learning Health System
Crandall, Wallace, Joffe, Marshall M., Colletti, Richard B. , Adler, Jeremy, Baron, Howard, Berman, James , Rosario, J. Fernando del , Grossman, Andrew B., Israel, Esther J. , Kim, Sandra C. , Lightdale, Jenifer R. , Margolis, Peter A. , Marsolo, Keith , Mehta, Devendra I. , Milov, David E., Patel, Ashish , Tung, Jeanne , Forrest, Christopher B. , Bailey, L. Charles , Zhang, Peixin , Adler, Jeremy, Hoffenberg, Edward J. , Kappelman, Michael D. , Adler, J

Mayo Clinic

Pediatrics | June 17, 2014 | Volume: 134 | Issue: 1 | Pages: 37-44

10.1542/peds.2013-4103 | PMID 24935993 Get It

OBJECTIVES: ImproveCareNow (ICN) is the largest pediatric learning health system in the nation and started as a quality improvement collaborative. To test the feasibility and validity of using ICN data for clinical research, we evaluated the effectiveness of anti-tumor necrosis factor-α (anti-TNFα) agents in the management of pediatric Crohn disease (CD). METHODS: Data were collected in 35 pediatric gastroenterology practices (April 2007 to March 2012) and analyzed as a sequence of nonrandomized trials. Patients who had moderate to severe CD were classified as initiators or non-initiators of anti-TNFα therapy. Among 4130 patients who had pediatric CD, 603 were new users and 1211 were receiving anti-TNFα therapy on entry into ICN. RESULTS: During a 26-week follow-up period, rate ratios obtained from Cox proportional hazards models, adjusting for patient and disease characteristics and concurrent medications, were 1.53 (95% confidence interval [CI], 1.20–1.96) for clinical remission and 1.74 (95% CI, 1.33–2.29) for corticosteroid-free remission. The rate ratio for corticosteroid-free remission was comparable to the estimate produced by the adult SONIC study, which was a randomized controlled trial on the efficacy of anti-TNFα therapy. The number needed to treat was 5.2 (95% CI, 3.4–11.1) for clinical remission and 5.0 (95% CI, 3.4–10.0) for corticosteroid-free remission. CONCLUSIONS: In routine pediatric gastroenterology practice settings, anti-TNFα therapy was effective at achieving clinical and corticosteroid-free remission for patients who had Crohn disease. Using data from the ICN learning health system for the purpose of observational research is feasible and produces valuable new knowledge.
Effects of traumatic brain injury and posttraumatic stress disorder on Alzheimer's disease in veterans, using the Alzheimer's Disease Neuroimaging Initiative
Weiner, Michael W. , Veitch, Dallas P. , Aisen, Paul, Petersen, Ronald C. , Jagust, William, Trojanowski, John Q. , Shaw, Leslie M. , Saykin, Andrew J. , Harvey, Danielle , Pacifico, Anthony, Sheline, Yvette I. , Yaffe, Kristine , Mohlenoff, Brian, Hayes, Jacqueline , Neylan, Thomas C. , Grafman, Jordan Henry , Jack, Clifford R. , Green, Robert C. , Toga, Arthur W. , Friedl, Karl E. , Saykin, Andrew J , Harvey, Danielle J

Mayo Clinic

Alzheimer's & Dementia | June 9, 2014 | Volume: 10 | Issue: 3S | Pages: No page available

10.1016/j.jalz.2014.04.005 | PMID 24924673 Get It

AbstractBoth traumatic brain injury (TBI) and posttraumatic stress disorder (PTSD) are common problems resulting from military service, and both have been associated with increased risk of cognitive decline and dementia resulting from Alzheimer's disease (AD) or other causes. This study aims to use imaging techniques and biomarker analysis to determine whether traumatic brain injury (TBI) and/or PTSD resulting from combat or other traumas increase the risk for AD and decrease cognitive reserve in Veteran subjects, after accounting for age. Using military and Department of Veterans Affairs records, 65 Vietnam War veterans with a history of moderate or severe TBI with or without PTSD, 65 with ongoing PTSD without TBI, and 65 control subjects are being enrolled in this study at 19 sites. The study aims to select subject groups that are comparable in age, gender, ethnicity, and education. Subjects with mild cognitive impairment (MCI) or dementia are being excluded. However, a new study just beginning, and similar in size, will study subjects with TBI, subjects with PTSD, and control subjects with MCI. Baseline measurements of cognition, function, blood, and cerebrospinal fluid biomarkers; magnetic resonance images (structural, diffusion tensor, and resting state blood‐level oxygen dependent (BOLD) functional magnetic resonance imaging); and amyloid positron emission tomographic (PET) images with florbetapir are being obtained. One‐year follow‐up measurements will be collected for most of the baseline procedures, with the exception of the lumbar puncture, the PET imaging, and apolipoprotein E genotyping. To date, 19 subjects with TBI only, 46 with PTSD only, and 15 with TBI and PTSD have been recruited and referred to 13 clinics to undergo the study protocol. It is expected that cohorts will be fully recruited by October 2014. This study is a first step toward the design and statistical powering of an AD prevention trial using at‐risk veterans as subjects, and provides the basis for a larger, more comprehensive study of dementia risk factors in veterans.
Anterior spinal artery infarction causing man-in-the-barrel syndrome
Flanagan, Eoin P. , McKeon, Andrew , Weinshenker, Brian G. , Flanagan, E P , McKeon, Andrew

Mayo Clinic

Neurology Clinical Practice | June 9, 2014 | Volume: 4 | Issue: 3 | Pages: 268-269

10.1212/cpj.0000000000000032 | PMID 29473573 Get It